Relafen 750 showcases a significant case study within the biochemical pharmacy field. The mechanism of action fundamentally impacts cyclooxygenase proteins, specifically both COX isoforms, diminishing the synthesis of pain signals. Given a cellular analysis, Relafen's clinical benefit copyrights on this capacity to selectively inhibit tissue damage